Evidence map›Paper›PMID 24424175›Full record

ReviewAutoimmunity reviews

The IL-23/IL-17 axis in psoriatic arthritis.

Erika Suzuki, Elizabeth D Mellins, M Eric Gershwin, Frank O Nestle, Iannis E Adamopoulos

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Autoimmunity reviews. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 7 pooled it
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 7 syntheses or guidelines pooled it, 174 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The role of IL-17 and Th17 cells in keloid pathogenesis.Archives of dermatological research · 2024
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Review
  13. Chemogenetic Activation of GFASEB bioAdvances · 2026
    Article
  14. Article
  15. Review
  16. Review
  17. Interferon-JAK-STAT Axis in Bone Metabolism.Current osteoporosis reports · 2026
    Review
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Erika SuzukiDepartment of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA 95616, USA.
Elizabeth D MellinsDivisions of Human Gene Therapy and Pediatric Rheumatology, Program in Immunology, Stanford University, Palo Alto, CA 94305, USA.
M Eric GershwinDepartment of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA 95616, USA.
Frank O NestleSt. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London School of Medicine, Guy's Hospital, London, United Kingdom.
Iannis E AdamopoulosDepartment of Internal Medicine, Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, CA 95616, USA; Institute for Pediatric Regenerative Medicine, Shriners Hospitals for Children Northern California, CA 95817, USA. Electronic address: iannis@ucdavis.edu.
University of California, Davis · USGuy's Hospital · GBStanford University · US

Funding

UC Davis Clinical and Translational Science CenterUL1TR000002 · NCATS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI BERGLUND, LARS F · 2012 to 2015
$12.2M
The IL-23/IL-17 Axis in Inflammatory ArthritisR01AR062173 · NIAMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI LEVY, DAN · 2012 to 2025
$4.9M
A role for IL-1 in SJIA monocyte phenotypes: A RAPPORT ancillary studyR01AR061297 · NIAMS · STANFORD UNIVERSITY · PI MELLINS, ELIZABETH D · 2010 to 2013
$1.2M
Medical Research Council MR/J006742/1NCATS NIH HHS UL1 TR000002NCATS NIH HHS UR1 TR000002NIAMS NIH HHS AR62173NIAMS NIH HHS R01 AR061297NIAMS NIH HHS R01AR061297NIAMS NIH HHS R01 AR062173
6 · The paper itself

Abstract

Psoriatic arthritis (PsA) is an immune-mediated chronic inflammatory disease, affecting both the skin and joints. Disease progression is associated with aberrant cytokine expression, and TNF blockade is the most successful therapy to date. However, not all patients are responsive to anti-TNF treatment, highlighting the need to better understand the cellular and molecular mechanisms that govern the disease. PsA associations with single nucleotide polymorphisms in IL23R as well as TRAF3IP2 (Act1), a molecule downstream of the IL-17 receptor (IL-17R), have linked the IL-23/IL-17 axis to disease pathology. Although both cytokines are implicated in PsA, a full picture of their cellular targets and pathogenic mechanisms has not yet emerged. In this review, we focus on the IL-23/IL-17 axis-elicited responses mediated by osteoclasts, keratinocytes and neutrophils. Expanding our understanding of the cellular and molecular mechanisms that dictate pathogenicity in PsA will contribute to developing novel treatment strategies to combat disease.

Indexed as

AnimalsArthritis, PsoriaticHumansInterleukin-17Interleukin-23NeutrophilsOsteoclastsRANK LigandInterleukin-17Interleukin-23RANK LigandIL-17IL-23NF-κBPsoriatic arthritis

Identifiers

PMID24424175
PMCPMC3995976
OpenAlexW2041959340

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.